Cardiovascular's net sales for the three and six months ended October 28, 2022 were $2.8 billion and $5.5 billion, respectively, a decrease of 2 percent and 4 percent, respectively, compared to the corresponding periods in the prior fiscal year.Medical Surgical's net sales for the three and six months ended October 28, 2022 were $2.1 billion and $4.1 billion, respectively, a decrease of 10 percent and 12 percent, respectively, compared to the corresponding periods in the prior fiscal year.Neuroscience’ s net sales for the three and six months ended October 28, 2022 were $2.2 billion and $4.3 billion, respectively, an increase of 2 percent and a decrease of 1 percent, respectively, compared to the corresponding periods in the prior fiscal year.In May and June 2022, Medtronic Luxco borrowed an aggregate of ¥297 billion, or approximately $2.3 billion, of the term loan, under the Fiscal 2023 Loan Agreement.The six months ended October 29, 2021 included $58 million of inventory write-downs associated with our June 2021 decision to stop the distribution and sale of Medtronic's HVAD System (MCS charges).Gains on equity method and minority investments were $12 million and $15 million for the three and six months ended October 28, 2022, respectively, compared to a loss of $5 million and gain of $38 million for the three and six months ended October 29, 2021, respectively.The net sales decrease for both periods was primarily driven by unfavorable currency impact and supply chain challenges in certain businesses.The decrease in net sales for both periods was primarily driven by unfavorable currency impacts and declines in the U. S. across most product lines.Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $1.7 billion in connection with the Enterprise Excellence program.The charges of $668 million primarily included $409 million of intangible asset impairments and $211 million for commitments and obligations, including customer support obligations, restructuring, and other associated costs.The decrease in net cash was partially offset by a decrease in cash paid to employees.Senior Notes for $1.9 billion of total consideration, and $368 million of Medtronic Luxco Senior Notes for $376 million of total consideration.(3) Includes receivables due from non-guarantor subsidiaries of $17.2 billion and $6.9 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.(4) Includes loans receivable due from non-guarantor subsidiaries of $6.5 billion and $8.4 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.(5) Includes payables due to non-guarantor subsidiaries of $28.8 billion and $20.1 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.(6) Includes loans payable due to non-guarantor subsidiaries of $27.8 billion and $46.6 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.(3) Includes receivables due from non-guarantor subsidiaries of $20.2 billion and $6.9 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.(4) Includes loans receivable due from non-guarantor subsidiaries of $6.5 billion and $8.3 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.(6) Includes loans payable due to non-guarantor subsidiaries of $29.0 billion and $46.4 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.